BioSpace News Archive

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2022.

AmerisourceBergen Corporation announced that its Board of Directors has elected Redonda Miller, M.D., 56, as a new independent director, effective January 1, 2023.

Vyant Bio, Inc. is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Owens & Minor, Inc. (NYSE: OMI) announced today that executive leadership will participate in a virtual fireside chat at the upcoming 5th Annual Evercore ISI HealthCONx Conference.

Maravai LifeSciences, Inc. announced it ranked 270 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28th year.

Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Seoul National University Bundang Hospital Biomedical Research Institute announced that it concluded the MOU on November 15, 2022, to standardize clinico genomic research using Cipherome, Inc.’s precision medicine research platform at Precision Medicine Center.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a Phase 1 study to evaluate the safety, tolerability and immunogenicity of a next generation COVID-19 vaccine candidate that aims to enhance SARS-CoV-2 T cell responses and potentially broaden protection against COVID-19.

Ardelyx, Inc. (Nasdaq: ARDX) today announced the vote of the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting for XPHOZAH for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.

BIOXYTRAN, INC. announced positive topline safety and efficacy results of its randomized, placebo-controlled Phase 2 clinical trial in 34 patients with mild-to-moderate COVID-19.